Thiamethoxam induced mouse liver tumors and their relevance to humans

Toxicological Sciences

Volumn 86, Issue 1, 2005, Pages 36-47

  Green, Trevor ^a   Toghill, Alison ^a   Lee, Robert ^a   Waechter, Felix ^a   Weber, Edgar ^a,b   Noakes, James ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^b DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

Liver tumors; Mode of action; Thiamethoxam

Indexed keywords

CARBON TETRACHLORIDE; CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INSECTICIDE; THIAMETHOXAM; UNCLASSIFIED DRUG; CARCINOGEN; NITRO DERIVATIVE; OXAZINE DERIVATIVE; PESTICIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER TOXICITY; LIVER TUMOR; MALE; METABOLITE; MOUSE; NONHUMAN; ANIMAL; BLOOD; BODY WEIGHT; CELL DIVISION; CHEMICALLY INDUCED DISORDER; DIET; DOSE RESPONSE; DRUG EFFECT; NICK END LABELING; ORGAN SIZE; PATHOLOGY;

ANIMALS; BODY WEIGHT; CARCINOGENS; CELL DIVISION; CHOLESTEROL; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; IN SITU NICK-END LABELING; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; NITRO COMPOUNDS; ORGAN SIZE; OXAZINES; PESTICIDES;

EID: 26944438720     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfi124     Document Type: Article

References (35)

1. Bradham, C. A., Plumpe, J., Manns, M. P., Brenner, D. A., and Trautwein, C. (1998). Mechanisms of hepatic injury. I. TNF-induced liver injury. Am. J. Physiol. 275, G387-G392.
2. Brennan, P. A., and Moncada, S. (2002). From pollutant gas to biological messenger: The diverse actions of nitric oxide in cancer. Ann. R. Coll. Surg. Engl. 84, 75-78.
3. Carmichael, N. G., Enzmann, H., Pate, I., and Waechter, F. (1997). The significance of mouse liver tumor formation for carcinogenic risk assessment: Results and conclusions from a survey of ten years of testing. Environ. Health Perspect. 105, 1196-1203.
4. Dolbeare, F. (1995a). Bromodeoxymidine: A diagnostic tool in biology and medicine, Part I: Historical perspectives, histochemical methods and cell kinetics. Histochem. J. 27(5), 339-369.
5. Dolbeare, F. (1995b). Bromodeoxymidine: A diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Histochem. J. 27(12), 923-964.
6. Dolbeare, F. (1996). Bromodeoxymidine: A diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. Histochem. J. 28(8), 531-575.
7. Dunn, O. J. (1964). Multiple comparisons using rank sums. Technometrics 6, 241-252.
8. Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Amer. Stat. Assoc. 50, 1096-1121.
9. EPA (2003). Draft Final Guidelines for Carcinogen Risk Assessment, U.S. Environmental Protection Agency, Washington DC.
10. Federal Register (2003). Clothianidin; Pesticide Tolerance. Federal Register, May 30th, Vol. 68, No. 104.
11. Gad, S. C., and Weil, C. S. (1986). Statistics and Experimental Design for Toxicologists. The Telford Press, Caldwell, NJ.
12. Garvey, E. P., Oplinger, J. A., Tanoury, G. J., Sherman, P. A., Fowler, M., Marshall, S., Harmon, M. F., Paith, J. E., and Furfine, E. S. (1994). Potent and selective inhibition of human nitric oxide synthase: inhibition by non-amino acid isothioureas. J. Biol. Chem. 269, 26669-26676.
13. Garvey, E. P., Oplinger, J. A., Furfine, E. S., Kiff, R. J., Laszlo, F., Whittle, B. R. J., and Knowles, R. G. (1997). 1400W is a slow tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J. Biol. Chem. 272, 4959-4963.
14. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. (1992). Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J. Cell Biol. 119, 493-501.
15. Gerson, R. J., MacDonald, J. S., Alberts, A. W., Kornburst, D. J., Maika, J. A., Stubbs, R. J., and Bokelman, D. L. (1989). Animal safety and toxicology of simvastatin and related hydroxyl-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87, 4A-28S-4A-38S.
16. Green, T., Toghill, A., Lee, R., Waechter, F., Weber, E., Peffer, R., Noakes, J., and Robinson, M. (2005). Thiamethoxam induced mouse liver tumors and their relevance to humans. Part 2: Species differences in response. Toxicol. Sci. 86, 48-55.
17. Hill, A. B. (1965). The environment and disease: Association or causation? Proc. Royal Soc. Med. (Section of Occupational Medicine; Meeting January 14, 1965) 58, 295-300.
18. Honkakoski, P., Auriola, S., and Lang, M. A. (1992a). Distinct induction profiles of three phenobarbital-responsive mouse liver cytochrome P450 isozymes. Biochem. Pharmacol. 43, 2121-2128.
19. Honkakoski, P., Kojo, A., and Lang, M.A. (1992b). Regulation of the mouse liver cytochrome P450 2B subfamily by sex hormones and phenobarbital. Biochem. J. 285, 979-983.
20. ILSI (2003). Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D., Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33(6), 591-653.
21. Kelley, M., Womack, J., and Stephen, S. (1990). Effects of cytochrome P-450 monooxygenase inducers on mouse hepatic microsomal metabolism of testosterone and alkoxyresorufins. Biochem. Pharmacol. 39, 1991-1998.
22. Kim, P. K. M., Zamora, R., Petrosko, P., and Billiar, T. R. (2001). The regulatory role of nitric oxide in apoptosis. Int. Immunopharmacol. 1, 1421-1441.
23. Kruskal, W. H., and Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J. Amer. Stat. Assoc. 47, 583-621.
24. Lala, P. K., and Chakraborty, C. (2001). Role of nitric oxide in carcinogenesis and tumour progression. Lancet 2, 149-156.
25. Luster, M. I., Simeonova, P. P., Galluci, R., and Matheson, J. (1999). Tumour necrosis factor-α and toxicology. Crit. Rev. Toxicol. 29, 491-511.
26. MacDonald, J. S., Gerson, R. J., Kornburst, D. J., Kloss, M. W., Prahalada, S., Berry, P. H., Alberts, A. W., and Bokelman, D. L. (1988). Preclinical evaluation of lovastatin. Am. J. Cardiol. 62, 16J-27J.
27. Maienfisch, P., Huerlimann, H., Rindlisbacher, A., Gsell, L., Dettwiler, H., Haettenschwiler, J., Sieger, E., and Walti, M. (2001). The discovery of thiamethoxam: A second generation neonicotinoid. Pest. Management Sci. 57, 165-176.
28. Morio, L. A., Chiu, H., Sprowles, K. A., Zhou, P., Heck, D. E., Gordon, M. K., and Laskin, D. L. (2001). Distinct roles of tumour necrosis factor-α and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicol. Appl. Pharmacol. 172, 44-51.
29. Newman, T. B., and Hulley, S. B. (1996). Carcinogenicity of lipid-lowering drugs. J. Amer. Med. Assoc. 275, 55-60.
30. Pastoor, T., Rose, P., Lloyd, S., Peffer, R., and Green, T. (2005). Case study: Weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors. Toxicol. Sci. 86, 56-60.
31. Rendon, A., Boucher, J.-L., Sari, M.-A., Delaforge, M., Ouazzani, J., and Mansuy, M. (1997). Strong inhibition of neuronal nitric oxide synthase by the calmodulin antagonist and anti-estrogen drug tamoxifen. Biochem. Pharmacol. 54, 1109-1114.
32. Taylor, B. S., Alarcon, L. H., and Billiar, T. R. (1998). Inducible nitric oxide synthase in the liver: Regulation and function. Biochemistry (Moscow) 63, 766-781.
33. Von Keutz, E., and Schluter, G. (1998). Preclinical safety evaluation of cerivastatin, a novel HMGCoA reductase inhibitor. Am. J. Cardiol. 82, 11J-17J.
34. Wang, Y., Vodovotz, Y., Kim, P. K. M., Zamora, R., and Billiar, T. R. (2002). Mechanisms of hepatoprotection by nitric oxide. Ann. N. Y. Acad. Sci. 962, 415-422.
35. Whysner, J., Ross, P. M., and Williams, G. M. (1996). Phenobarbital mechanistic data and risk assessment: Enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 153-191.